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Background: The essential clinical diagnostic components of brain death must include evidence for an established
etiology capable of causing brain death, two independent clinical confirmations of the absence of all brainstem
reflexes and an apnea test, and exclude confounders that can mimic brain death. Numerous confounders can
render the clinical neurological determination of death (NDD) virtually impossible. As such, clinicians must rely on
additional ancillary testing.
Methods/design: We will conduct a systematic review and a meta-analysis of ancillary testing for the neurological
determination of death. The primary objective of this systematic review is to evaluate the accuracy of these ancillary
tests compared to the three accepted reference standards: (1) clinical diagnosis, (2) four-vessel angiography and (3)
radionuclide imaging. This objective will be investigated using two different populations with different baseline risks
of brain death: comatose patients and patients with a neurological determination of death. We will search MEDLINE,
EMBASE and the Cochrane Central databases for retrospective and prospective diagnostic test studies and interventional
studies. We will report study characteristics and assess methodological quality using QUADAS-2, which is used to assess
the quality of diagnostic tests. If pooling is appropriate, we will compute parameter estimates using a bivariate model
to produce summary receiver operating curves, summary operating points (pooled sensitivity and specificity), and 95%
confidence regions around the summary operating point. Clinical and methodological subgroup and sensitivity
analyses will be performed to explore heterogeneity.
Discussion: The results of this project will provide a critical evidence base for the neurological determination of
death. The results will help clinicians to select ancillary tests based on the best available evidence. Our systematic
review will also identify the strengths and weaknesses in the current evidence for the use of ancillary tests in
diagnosing brain death. It will serve as a foundation for further research and the development of prospective
studies on currently used or novel techniques for NDD.
Protocol registration: PROSPERO Registration Number: CRD42013005907Background
For many patients with terminal heart, lung, liver or kidney
disease, organ transplantation is the treatment of choice
and most often their only hope for survival. In 2011, 4,660
patients were on the waiting lists for transplantation in
Canada and 285 died waiting for an organ [1]. Organs
harvested after the neurological determination of death
(NDD) are the principal source of organs transplanted
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stated.total of 1,518 organs for transplantation. In comparison,
152 organs were transplanted using 92 donations after
cardiac death [1]. The only sources for heart, pancreas
and intestine transplantation are NDD donors.
Before retrieving a vital organ from a donor with the
aim of transplantation, clinicians have to be 100% sure
that the donor is deceased. Social laws and norms
around the world follow what is termed the ‘dead donor
rule’: that is, organ retrieval itself cannot cause death [2].
As such, death must be diagnosed before the retrieval of
an organ.
Organs can be obtained from donors after either
cardiac death or brain death. NDD is a socially acceptedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Chassé et al. Systematic Reviews 2013, 2:100 Page 2 of 8
http://www.systematicreviewsjournal.com/content/2/1/100determination of death which describes the concept of
irreversible loss of capacity for consciousness combined
with the irreversible loss of all brainstem functions
including the capacity to breathe [3]. When a patient
meets the required criteria for NDD, they are legally
declared dead. Life–sustaining therapy can then be with-
drawn and, if the patient is eligible for organ donation,
their organs can be retrieved for transplantation.
This diagnosis of brain death is predominantly clinical
[4]. The essential clinical diagnostic components of brain
death vary between jurisdictions but usually include
evidence for an established etiology capable of causing
brain death, one or two independent clinical confirmations
of the absence of all brainstem reflexes and an apnea
test, and exclude confounders that can mimic brain
death [5,6]. Numerous confounders, such as the use of
barbiturates or other medications, severe craniofacial
trauma that prevents an appropriate clinical neurological
examination, and high cervical spine injuries that prevent
the performance of the apnea test, can render the NDD
virtually impossible.
In situations where a complete and accurate clinical
evaluation is impossible, clinicians must use additional
tests, called ancillary tests, to confirm the neurological
death of the patient [5,6]. Ancillary tests should be able
to demonstrate the absence of brain blood flow in the
cerebral hemispheres and in structures from the posterior
fossa [7]. An ideal test should never give any false-positive
results (brain death when in fact the patient is not
dead) and should be fast to perform, safe, readily available,
accessible, non-invasive, inexpensive, not susceptible to
confounding factors and standardized [4-6,8].
Limitations of evidence
Brain blood flow imaging, such as four-vessel angiography,
and functional tests, such as radionuclide imaging, have
traditionally been used as the gold standard ancillary
tests for NDD [4]. Recently, several additional ancillary
tests, such as computed tomography (CT) angiography,
CT perfusion, magnetic resonance angiography and xenon
CT, have been proposed as replacements for these
traditional tests to confirm NDD [4] and their clinical
use despite the absence of proper validation is growing
[7,9]. From a recent American survey, physicians used
several different ancillary tests for the same patient
and often used tests that were either not recommended
or not validated [9]. Significant institutional and clinical
practice variability thus remains in the use of ancillary
tests, their indication and their diagnostic criteria [4,9,10].
Furthermore, when ancillary tests were applied on
clinically brain-dead patients, a small proportion of the
patients presented detectable brain perfusion, suggesting
at best inaccuracy in the diagnostic criteria used for these
ancillary tests and at worst a population that would havereceived a diagnosis of brain death based on current
clinical criteria but in whom there is residual blood
flow [11,12]. Recently, the traditionally accepted accuracy
of four-vessel angiography for NDD has even been chal-
lenged [13]. Although a recent Canadian expert consensus
reported that the validation of ‘current or evolving tech-
niques of brain blood flow imaging should not evolve
into practice in a manner similar to cerebral angiography
and radionuclide scanning, based on clinical application’,
it is acknowledged that currently used ancillary tests
and even traditionally accepted gold standards for NDD
have not been subjected to rigorous evaluation [7]. The
same group issued recommendations for more research
to confirm the validity and accuracy of current ancillary
reference tests and to develop new techniques for NDD [7].
Methods/design
Research objectives
The primary objective of this systematic review is to
evaluate the accuracy of ancillary tests for the neurological
determination of death compared to the three accepted
reference standards: (1) clinical diagnosis, (2) four-vessel
angiography and (3) radionuclide imaging. This objective
will be investigated using two different populations with
different baseline risks of brain death: comatose patients
and patients with NDD. Our secondary objective is to
determine the prevalence of false negatives (patients
not declared dead by ancillary testing when they are in
fact dead) and false positives (patients declared dead by
ancillary testing when they are in fact not dead). Finally,
our tertiary objective is to determine the safety of the
different ancillary tests used for NDD.
Research approach
The methods used for this systematic review will follow
strict methodological standards based on the Cochrane
Collaboration Diagnostic Accuracy Working Group’s [14]
recommendations. Our approach will include, in addition
to our research goals and objectives, a thorough process
for study identification and selection and a descriptive
quality assessment of included studies. The data analysis,
presentation and interpretation will be adapted for this
systematic review of diagnostic test accuracy [15].
Target condition and study participants
Primary studies of ancillary tests for NDD have been
conducted in two different populations. In systematic
reviews of diagnostic tests, it is important to consider
the different pre-test probabilities since they can influence
the estimation of the sensitivity and specificity of the
studied test [16]. For NDD, since the specificity of a
test is the most important parameter to estimate (that
is, we do not want to declare death for someone who is
not dead), it is very important to know how the test
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patients) with characteristics similar to our target popula-
tion (brain-dead patients). For this review, we will consider
two groups of patients from: (1) studies of patients with
a clinical diagnosis of brain death and (2) studies of coma-
tose patients with a brain injury who underwent ancillary
testing to diagnose brain death. Some studies will have
included patients with various coma criteria with no
NDD but for whom ancillary testing was performed for
NDD. Therefore, we will include two types of study for
this population type: studies where the same set of criteria
for inclusion was used for the whole cohort (cohort
accuracy studies) and studies where there was a different
set of inclusion criteria for NDD cases compared to coma-
tose controls (case–control accuracy studies) [16].
Reference standards
From our initial literature search, and based on current
clinical practice and guidelines, we will consider studies
that used one of the three reference gold standards for
NDD [7]:
 Clinical diagnosis: An established cause of brain
injury, absence of confounding (as stated by the
authors), coma, absence of brainstem reflexes,
apnea. We are aware that clinical diagnosis criteria
have changed over time and vary depending on the
country where the study was conducted. If the
clinical diagnosis is incomplete according to the
aforementioned criteria, but the authors cite and
explain their clinical diagnosis criteria, the study will
be included in the review.
 Four-vessel angiography: No intracranial blood flow
(beyond carotid bifurcation or circle of Willis).
 Radionuclide imaging: Hollow skull phenomenon,
absence of intracranial uptake or equivalent.
In some jurisdictions, an ancillary test, such as an
electroencephalogram or transcranial Doppler test, is
mandatory as part of the clinical diagnosis [17]. In
studies where an ancillary test was used as part of the
clinical diagnosis, we will consider the combination of the
clinical evaluation and the ancillary test as the clinical
diagnosis. We will document the clinical diagnosis plus
the ancillary testing as a reference and perform subgroup
analyses at a later stage (by comparing the diagnosis to a
clinical diagnosis that does not include an ancillary test).
Studied tests
We will investigate the following ancillary tests that have
been proposed or are currently in use for NDD: four-vessel
angiography, radionuclide imaging using any tracer, trans-
cranial Doppler testing, electroencephalogram, evoked
potentials, CT angiography, CT perfusion scan, magneticresonance angiography, magnetic resonance perfusion,
PET scan and xenon CT. Four-vessel angiography and
radionuclide imaging will be included in the analysis as
either reference standards or studied tests depending
on the definition of the clinical diagnosis. All ancillary
tests will be compared to one of our three reference
standards (clinical diagnosis, four-vessel angiography
and radionuclide imaging).
Type of studies
We will include all retrospective and prospective diagnostic
test studies (including cross-sectional and cohort studies)
and interventional studies. Our aim in synthesizing all
available evidence is to provide not only estimates of
diagnostic accuracy but also to highlight the clinical
and methodological quality of the evidence as well as
important gaps in the evidence.
Search strategy
We will develop a comprehensive search strategy with an
information specialist trained in the conduct of systematic
reviews. We will use MESH (or the EMTREE equivalent)
terms and free-text terms for the included population,
studied tests and reference tests that are as sensitive and
inclusive as possible (Appendix 1). We will search the
MEDLINE, EMBASE and Cochrane Central databases
(including the Cochrane Database of Systematic Reviews,
the Cochrane Central Register of Controlled Trials, the
Cochrane Methodology Register, the Database of Abstracts
of Reviews of Effects, the Health Technology Assessment
Database and the NHS Economic Evaluation Database)
from their inception to the date when the authors are
ready for the final abstraction of the selected references.
The reference lists of all published narrative reviews,
systematic reviews and eligible studies will be searched
for additional references.
Study screening and inclusion
We will use the title and the abstract to select the studies
for inclusion after the comprehensive search has been
performed. If no abstract is available, the full text will
be obtained unless the title shows the study is clearly
irrelevant. The same inclusion and exclusion criteria
will be used at each screening step. For the first step,
from the abstracts and titles, a single author will exclude
studies clearly irrelevant to brain death or ancillary testing.
A 10% random sample of all potential references will
be validated by a second author for agreement. A sec-
ond screening will then be performed by at least two
independent reviewers for each study that was not
excluded at the first step. Full text copies of relevant
reports will be obtained for independent analysis by
two reviewers, who will make the final inclusion decision.
Chassé et al. Systematic Reviews 2013, 2:100 Page 4 of 8
http://www.systematicreviewsjournal.com/content/2/1/100Disagreements will be solved by consensus and consult-
ation with a third author.
Inclusion criteria
Population and target condition
 The studied population was either diagnosed brain
dead patients or comatose patients who received
ancillary testing for NDD (see population
description above).
Studied tests and reference standard
 For studies where patients are selected based on
clinical NDD, only one ancillary test will be compared
to the clinical diagnosis as the reference standard.
 For studies where NDD was not clinically diagnosed
before conducting an ancillary test, the reference
test for the studied ancillary test will have to be either
radionuclide imaging or four-vessel angiography. If
these criteria are not met (for example, if a study
performs only an ancillary test that diagnoses
brain death without comparing the diagnosis to
an accepted reference test), the study will not
be included.
 For studies where patients are included based on
their comatose state, the studied ancillary test has to
be compared to at least one of the reference
standards: clinical diagnosis, four-vessel angiography
or radionuclide imaging.
Exclusion criteria
 Studies from which we cannot obtain or calculate
the true and false positive and negative rates
from the text, appendices or after contacting the
main authors.
 Studies for which the objective was to determine
diagnostic criteria of a specific ancillary test with
no a priori definition of the diagnostic criteria to
be used to define brain death.
 Studies where only a single ancillary test was
performed without any reference test.
 Case reports (≤2 cases).
 Duplicates or sub-cohorts of already published
cohorts.
Analysis plan
For our primary and secondary objectives, a descriptive
analysis of all included studies will be listed in tables and
as text. The clinical, demographic and methodological
quality characteristics of the reference and ancillary
tests and the results will be reported and discussed. An
in-depth discussion of the variability between studieswill be provided where applicable. We will perform
meta-analyses of suitable studies and discuss the results.
Study characteristics
Each study will be categorized as observational or inter-
ventional. Interventional studies will be categorized as
randomized or non-randomized, and observational studies
will be further categorized as prospective (cohort) or
retrospective (cohort or case–control). Other character-
istics of each study design will be reported. We will
describe the population studied including the total
number of patients, clinical characteristics, presence of
confounding factors, the number of NDD patients, the
number of patients in control groups where applicable
and the characteristics of the patients (age, gender and
reasons for brain death) and we will also list the inclusion
and exclusion criteria and the criteria used for the ref-
erence and ancillary tests.
Risk of bias
We expect that most of the included studies will be
observational in nature. Diagnostic meta-analyses of
observational studies may be more prone to bias [15].
For the current systematic review, particular care will
be taken to investigate the methodological and clinical
risk of bias adequately before proceeding with the
meta-analysis [15].
Methodological quality assessment
The methodological quality of the studies included in this
systematic review will be evaluated by two independent
reviewers using the QUADAS-2 tool, which is used to
assess the quality of diagnostic tests [18]. QUADAS-2
is an updated version of this evidence-based quality tool.
It is used in systematic reviews of diagnostic accuracy
studies and is recommended by the Cochrane Collabor-
ation Diagnostic Accuracy Working Group [14]. This tool
helps to evaluate the principal methodological risk of
bias in systematic reviews of diagnostic test accuracy [15].
Specific coding instructions adapted for this review will
be included for the reviewers. Overall and study-specific
appraisals of methodological strengths and weaknesses
will be reported.
Clinical risk of bias
Although most countries use similar criteria for NDD
[5], we may uncover differences in diagnosis practices
for the clinical reference standards. Moreover, although
clinical guidelines are available in most countries for
NDD, the way they are applied can vary [10]. It is thus
possible that clinical diagnosis criteria will vary across
studies. We will very carefully define the criteria used
for the clinical diagnosis of brain death for each included
trial and if possible contact the authors for further details.
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impact of the differences.
Similar issues may be observed for the diagnostic criteria
used for ancillary testing. The diagnostic criteria for NDD
for the ancillary tests used in each study will be collected
and analyzed to investigate the differences between them.
Technology has significantly changed over the years.
For example, in radionuclide imaging, the tracers infused
into patients for brain uptake have changed. In cases
where the exact diagnostic criteria used for NDD in an
ancillary test are not be available, we will attempt to
contact the authors for details.
Primary analysis
For each study we will collect the rates for true positives,
false positives, true negatives and false negatives and
compute from the crude data the sensitivity and speci-
ficity, positive likelihood ratio and negative likelihood
ratio. If possible and appropriate, parameter estimates
will be computed using a bivariate model to produce
summary receiver operating curves, summary operating
points (pooled sensitivity and specificity) and 95% con-
fidence regions around the summary operating point
[19,20]. These will be used to compare the accuracy of
ancillary tests. These analyses will be performed for the
following combinations:
1. Clinical NDD patients
a. Each ancillary test will be compared to the
clinical diagnosis.
b. Each ancillary test will be compared to four-vessel
angiography or radionuclide imaging.
2. Comatose patients
a. Each ancillary test will be compared to the
clinical diagnosis.
b. Each ancillary test will be compared to four-vessel
angiography or radionuclide imaging.
3. For case–control diagnostic test studies, we will
evaluate the possibility of pooling NDD groups and
comatose groups to their respective population.
Results before and after the inclusion of these
patients will be reported.
Secondary and tertiary analyses
For the secondary analysis, we will report isolated brain-
stem death prevalence, false positive and false negative
rates and a description of the cases. We will also report
what the authors considered as confounding factors in
their inclusion criteria for NDD. These data will be
obtained from both prospective and retrospective
studies. For our tertiary analysis, we will report the
safety of ancillary tests. We will collect all safety-related
events reported by the authors such as any delay in organ
retrieval due to the use of an ancillary test, adverse eventsfor the organ donor related to the use of contrast agents
(such as renal failure and allergic reactions) and adverse
events related to the transfer of unstable patients from
an intensive care unit.
Planned subgroup analyses to explain heterogeneity
In meta-analysis of diagnostic test studies, heterogeneity
is expected and univariate tests for heterogeneity are
usually not performed [20]. To explore clinical and
statistical heterogeneity, we will fit separate receiver
operating curves for these planned subgroups of patients:
(1) adults ≥18 years vs. mixed children/adults, only children
vs. only adults and we will consider subgroups for the
children (<1 month and neonates vs. children <18 years);
(2) use of an ancillary test combined with clinical diagnosis
as the reference standard, vs. clinical NDD alone, for a
given ancillary test; (3) time after clinical diagnosis of
brain death < or >24 hours; (4) studies that included
patients with confounders (craniectomy, anoxic brain
injury, hypothermia, barbiturates or other confounding
factor as stated by the authors) vs. not included and (5)
significant changes in ancillary test technology or diag-
nostic criteria.
Planned sensitivity analyses to study impact of study
design on ancillary test accuracy
Based on guidance provided by the Cochrane Collabor-
ation, we will use subgroups to explore and explain
any heterogeneity in test accuracy and we will perform
sensitivity analysis to investigate robustness [20]. It is
impossible to identify all potential sensitivity analyses,
but based on QUADAS-2 we can pre-specify important
sensitivity analyses that will have to be performed: risk
of selection bias, risk of interpretation bias for the
studied ancillary test and risk of bias introduced by the
interpretation of the reference test [18].
Discussion
The rigorous systematic review methodology used for
this project will ensure there is a synthesis of the best
available knowledge on this topic. The internal validation
and piloting undertaken at every step of the review will de-
crease the risk of selection bias and systematic extraction
errors. We will pilot and then use an evidence-based tool
to evaluate the methodological quality and we will use
the results in a pre-specified subgroup analysis to explore
potential methodological causes for heterogeneity.
The results from any systematic review will be, however,
highly dependent on the quality of the underlying primary
studies. For the current review, we are aware that most,
if not all studies will be cohort or case–control studies,
and many will be retrospective. We purposively decided
to be comprehensive in our eligibility criteria to better
appraise the extent of the available literature as we
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ancillary testing and NDD, including practice guidelines,
may be influenced by lower quality studies. As such, we
wish to compare the influence of lower quality studies
with those of higher quality.
The results of this project will be an important evidence
base for NDD. The results will be directly usable at the
bedside to help clinicians involved in NDD better
select adequate ancillary tests, based on the best available
evidence. The results will inform policymakers and
transplantation organizations regarding NDD and may
trigger an update of their recommendations and
guidelines for ancillary testing, not only regarding clinical
considerations, but also at the organizational level.
Not all tests are available in all settings (for example,
community vs. academic hospitals, primary centers vs.
tertiary centers, and so on) and recommendations adapted
to different contexts might be necessary (which test
and when, vs. transferring the patient for testing). The
results of our systematic review will also identify the
strengths and weaknesses in the current evidence for
the use of ancillary tests in diagnosing brain death.
They will serve as a foundation for further research and
the development of prospective studies on currently
used or novel techniques for NDD.
Appendix 1: Search strategy
Database: Embase Classic + Embase , Ovid MEDLINE(R)
In-Process & Other Non-Indexed Citations and Ovid
MEDLINE(R) <1946 to Present>
Search Strategy:
1 brain death/ (16664)
2 (brain dead or brain death).tw. (12323)
3 irreversible coma.tw. (328)
4 coma depasse.tw. (62)
5 cerebral death.tw. (744)
6 neurologic$ death.tw. (188)
7 absence of neuro$ function$.tw. (17)
8 (brain stem dea$ or cerebr$ circulatory arrest).tw. (667)
9 or/1-8 (20675)
10 hexamethylpropylene amine oxime technetium tc
99 m/ (4808)
11 single photon emission computer
tomography/ (43677)
12 (single photon emission computed tomography or
single photon emission ct or spect).tw. (54250)
13 digital subtraction angiography/ (20247)
14 digital subtraction angiography.tw. (12266)
15 positron emission tomography/ (99416)
16 scintiangiography/ or brain scintiangiography/ (2925)
17 (Xenon computed tomography or xenon ct).tw. (702)
18 magnetic resonance angiography/ (37369)
19 (magnetic resonance angiography or magnetic reson-
ance perfusion or mr perfusion).tw. (12951)20 (computed tomography angiography or ct angiog-
raphy).tw. (17741)
21 (computed tomography perfusion or ct perfusion).
tw. (2250)
22 Doppler echography/ (28156)
23 Transcranial Doppler.tw. (14109)
24 ancillary test$.tw. (1621)
25 ((brain or cerebral) adj perfusion).tw. (19821)
26 electroencephalography/ (212759)
27 (Electroencephalography or eeg).tw. (145251)
28 exp evoked response/ (95761)
29 (evoked response or evoked potentials).tw. (61141)
30 or/10-29 (660084)
31 9 and 30 (3489)
32 sensitiv$.tw. (2040984)
33 diagnostic accuracy/ (169708)
34 diagnostic.tw. (1048047)
35 or/32-34 (3021308)
36 9 and 35 (1135)
37 31 or 36 (4111)
38 case report/ (3581454)
39 37 not 38 (3554)
40 39 use emczd (2153) Embase
41 Brain Death/ (16664)
42 (brain dead or brain death).tw. (12323)
43 irreversible coma.tw. (328)
44 coma depasse.tw. (62)
45 cerebral death.tw. (744)
46 neurologic$ death.tw. (188)
47 absence of neuro$ function$.tw. (17)
48 (brain stem dea$ or cerebr$ circulatory arrest).
tw. (667)
49 or/41-48 (20675)
50 Technetium Tc 99 m Exametazime/du (1149)
51 Tomography, Emission-Computed, Single-
Photon/ (67876)
52 (single photon emission computed tomography or
single photon emission ct or spect).tw. (54250)
53 Angiography, Digital Subtraction/ (20247)
54 digital subtraction angiography.tw. (12266)
55 Positron-Emission Tomography/ (99416)
56 Radionuclide Angiography/ (3787)
57 (Xenon computed tomography or xenon ct).tw. (702)
58 Magnetic Resonance Angiography/ (37369)
59 (magnetic resonance angiography or magnetic reson-
ance perfusion or mr perfusion).tw. (12951)
60 (computed tomography angiography or ct angiog-
raphy).tw. (17741)
61 (computed tomography perfusion or ct perfusion).
tw. (2250)
62 Ultrasonography, Doppler, Transcranial/ (33717)
63 Transcranial Doppler.tw. (14109)
64 ancillary test$.tw. (1621)
65 ((brain or cerebral) adj perfusion).tw. (19821)
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67 (Electroencephalography or eeg).tw. (145251)
68 exp Evoked Potentials/ (190141)
69 (evoked potentials or evoked response).tw. (61141)
70 or/50-69 (720770)
71 49 and 70 (3508)
72 sensitiv$.mp. (2481844)
73 predictive value$.mp. (265327)
74 accurac$.tw. (464449)
75 72 or 73 or 74 (2950608)
76 49 and 75 (744)
77 71 or 76 (3944)
78 (case reports not review).pt. (1514784)
79 77 not 78 (3727)
80 79 use prmz (1457) Medline
81 40 or 80 (3610)
82 remove duplicates from 81 (2446)
Database: EBM Reviews - Cochrane Database of
Systematic Reviews <2005 to February 2013>, EBM
Reviews - ACP Journal Club <1991 to March 2013>,
EBM Reviews - Database of Abstracts of Reviews of
Effects <1st Quarter 2013>, EBM Reviews - Cochrane
Central Register of Controlled Trials < March 2013>,
EBM Reviews - Cochrane Methodology Register <3rd
Quarter 2012>, EBM Reviews - Health Technology
Assessment <1st Quarter 2013>, EBM Reviews - NHS
Economic Evaluation Database <1st Quarter 2013>
Search Strategy:
1 (brain death or brain dead).mp. (81)
2 irreversible coma.mp. (1)
3 coma depasse.mp. (1)
4 cerebral death.mp. (0)
5 neurologic$ death.mp. (10)
6 absence of neuro$ function$.mp. (0)
7 (brain stem dea$ or cerebr$ circulatory arrest).
mp. (10)
8 or/1-7 (96)
9 hexamethylpropylene amine oxime technetium tc
99 m.mp. (14)
10 single photon emission computer tomography.
mp. (97)
11 (single photon emission computed tomography or
single photon emission ct or spect).mp. (1109)
12 digital subtraction angiography.mp. (219)
13 positron emission tomography.mp. (1593)
14 scintiangiography.mp. (7)
15 (Xenon computed tomography or xenon ct).mp. (11)
16 (magnetic resonance angiography or magnetic reson-
ance perfusion or mr perfusion).mp. (458)
17 (computed tomography angiography or ct angiog-
raphy).mp. (272)
18 (computed tomography perfusion or ct perfusion).
mp. (26)19 Doppler echography.mp. (142)
20 Transcranial Doppler.mp. (610)
21 ancillary test$.mp. (30)
22 ((brain or cerebral) adj perfusion).mp. (470)
23 (Electroencephalography or eeg).mp. (5281)
24 (evoked potentials or evoked response).mp. (2638)
25 Contingent Negative Variation.mp. (183)
26 Event-Related Potentials.mp. (613)
27 Cochlear Microphonic Potentials.mp. (2)
28 (Vestibular adj3 Potentials).tw. (14)
29 or/9-28 (11532)
30 8 and 29 (11)
31 sensitiv$.mp. (49239)
32 predictive value$.mp. (7434)
33 accurac$.tw. (9658)
34 or/31-33 (58078)
35 8 and 34 (25)
36 30 or 35 (30)
37 remove duplicates from 36 (30)
Abbreviations
CT: Computed tomography; NDD: Neurological determination of death.
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